|
Establishment Labs Holdings Inc, a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has submitted Motiva implants for approval in primary and revision breast reconstruction to the US Food and Drug Administration (FDA). The products were previously approved by the US FDA for use in breast augmentation on September 27, 2024.
“Expanding our US FDA approval from breast augmentation to reconstruction is an important step forward for women’s health,” said Jeff Ehrhardt, senior vice president and Establishment Labs’ General Manager of North America. “Breast reconstruction has seen little innovation for more than a decade, despite these patients often needing improved and more advanced technology. This milestone brings us closer to offering the benefits of Motiva to women after mastectomy, providing the same proven technology that has seen rapid adoption in breast augmentation.”
The Motiva US IDE Study was conducted at 17 centres in the US and one centre in Western Europe and included 274 post-mastectomy reconstruction patients, including 220 primary and 54 revision patients. Motiva SmoothSilk Round and Ergonomix Implants represent state-of-the-art innovation in plastic surgery. These devices feature the patented SmoothSilk surface, designed for enhanced biocompatibility and scientifically shown to promote low inflammation. The Motiva SmoothSilk Ergonomix device is the first breast implant in the world that embodies the science of ergonomics, as it is designed to adapt, react, feel, and move like natural breast tissue. Motiva SmoothSilk Ergonomix implants are unique to the implant market, as their shape can adapt as the body changes position, maintaining a round shape when lying down and a teardrop shape when standing up. The Motiva SmoothSilk Round implants provide increased upper breast fullness and softness while keeping a round full form regardless of position. Since approval for breast augmentation in 2024, more than 60,000 Motiva implants have been sold in the United States.
“Successful breast reconstruction depends on aligning surgical technique with appropriate tools,” said Mark Clemens, MD, MBA, FACS, and Professor of Plastic Surgery at The University of Texas MD Anderson Cancer Center. “While surgical techniques have advanced significantly, innovation in reconstructive devices has been more gradual, making technologies that address real clinical limitations especially important. In my experience, the ability to safely image patients with MRI during the expansion process and to improve precision during radiation planning has made MRI-conditional tissue expanders, like Motiva Flora, a valuable addition to reconstructive care. The availability of a reconstruction indication for Motiva implants expands our options further, allowing surgeons to thoughtfully incorporate device characteristics such as unique surface design and clinical performance data into individualized reconstructive planning.”
The Motiva Flora tissue expander was cleared for use in the United States in 2023 and is in use at over 200 cancer centres for breast reconstruction following breast cancer. Flora is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional.
Establishment Labs Holdings offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech, a unique minimally invasive experience for breast harmonization, and Preservé, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM is a next generation minimally invasive system for gluteal ergonomic modelling currently undergoing an IRB approved pivotal study. The Motiva Flora tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zen, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals.
|